Coherence Neuro
Developing implantable bioelectronics and neuromodulation systems for oncology management.
Website: https://www.coherenceneuro.com
Cover Block
Open sources
| Field | Value |
|---|---|
| Company | Coherence Neuro |
| Tagline | Developing implantable bioelectronics and neuromodulation systems for oncology management. |
| Headquarters | San Francisco, United States [Tech Funding News, November 2025] |
| Founded | 2022 [Tech Funding News, November 2025] |
| Stage | Seed [Tech Funding News, November 2025] |
| Business model | Hardware + Software |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth profile | Venture Scale |
| Founding team | Co-Founders (2): Ben Woodington, Elise Jenkins [Tech Funding News, November 2025] |
| Funding label | Seed |
| Total disclosed funding | ~$10,000,000 [Tech Funding News, November 2025] |
Links
Open sources
- Website: https://www.coherenceneuro.com
- LinkedIn: https://www.linkedin.com/company/coherenceneuro
What an Investor Needs First
PUBLIC Coherence Neuro is building implantable neurotechnology for oncology, a category that merits investor attention because the company is pairing a brain-computer-interface style sensing stack with a closed-loop therapeutic ambition in glioma care, and it has now moved beyond concept framing into early human use of its investigational probe according to public reporting [Tech Funding News, November 2025] [massdevice.com] [WIRED]. Founded in 2022 by Ben Woodington and Elise Jenkins, the company is still early, but the public record points to a relatively focused origin: applying bioelectronic medicine to brain tumors rather than starting with a broader neuromodulation platform claim [Tech Funding News, November 2025] [Crunchbase].
The product architecture appears to center on two linked systems. Coherence describes SOMA-1 as a therapeutic implant intended to sense disease-linked electrical activity and deliver stimulation, while CIPHER is the thinner-film cortical interface being used in initial intraoperative work to capture data that could inform a later chronic implant strategy [Tech Funding News, November 2025] [TMG Pulse] [The World of Implantable Devices, January 2026]. That pairing is the main point of differentiation in the public materials: the company is not only recording signals during surgery, but trying to build toward continuous sensing and targeted intervention in glioblastoma, a substantially harder claim that will require careful clinical validation [massdevice.com] [ICI Innolabs, June 2026].
The founding team has some relevant technical grounding, although the public evidence is stronger on the technical side than on commercial execution. Woodington is identified publicly as co-founder and CEO, and Jenkins as co-founder and CTO; Jenkins also has prior links to Opto Biosystems and Cambridge PhD research focused on electrotherapy for brain tumours, which fits the companys scientific direction [Crunchbase] [Forbes] [Department of Engineering]. The operating footprint also looks intentionally split between San Francisco and Cambridge through current job postings, with roles spanning electrical engineering, clinical science, and surgical development [Ramp Jobs].
On financing, the cleanest confirmed datapoint is a $10 million seed round reported in November 2025, led by Topology Ventures with participation from Artesian, Blackbird, Possible Ventures, XEIA Venture Partners, Jumpspace Ventures, Divergent Capital, SmartGateVC, Spacewalk VC, and several angels [Tech Funding News, November 2025]. The business model is best understood, at this stage, as hardware plus software around investigational implantable systems rather than a near-term recurring software sale [Tech Funding News, November 2025] [coherenceneuro.com]. Over the next 12 to 18 months, the central watch items are whether Coherence can convert early intraoperative evidence into a clearer clinical development path for SOMA, expand human data beyond the reported three-patient probe use, and show that its sensing-to-stimulation thesis has practical value beyond technical feasibility [WIRED] [TMG Pulse] [The World of Implantable Devices].
Partially corroborated -- Relies on one independently reported financing article, supplemented by company-linked profiles and trade coverage with partial corroboration.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Hardware + Software |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Seed, total disclosed ~$10,000,000 |
Inside the Company
PUBLIC
Coherence Neuro enters the record as a young neurotechnology company with a narrow and unusually ambitious brief: implantable bioelectronics for cancer care. Public company profiles identify it as a San Francisco-based business founded in 2022 by Ben Woodington and Elise Jenkins, with Woodington listed as CEO and Jenkins as co-founder and CTO [Crunchbase]. The company website describes its approach more generally as treating disease with implantable electronic devices, which is directionally consistent with the corporate profile but still early enough that the public description remains program-level rather than commercial-stage [coherenceneuro.com].
The public milestone trail is short but coherent. Crunchbase places the company’s formation in 2022 and identifies a seed-stage financing history, while the company’s own materials frame its current work around an implantable system called SOMA for oncology-focused neuromodulation [Crunchbase] [coherenceneuro.com]. On the people side, Jenkins’s public background connects to prior neurotechnology work through Opto Biosystems and Cambridge engineering research on electrotherapy for brain tumours, which helps explain the technical continuity behind the company’s founding thesis [Crunchbase] [Department of Engineering] [Centre for Science and Policy].
The clearest dated milestone in the public record is the company’s disclosed $10 million seed round in November 2025, reported by Tech Funding News as led by Topology Ventures and Artesian, although funding detail is outside the narrower company-registry record requested for this section [Crunchbase] [Tech Funding News, November 2025]. Within the company-controlled record, the more recent operating signal is expansion hiring across engineering, clinical, operations, and human factors roles in San Francisco and Cambridge, which suggests the company is building both product-development and translational capability rather than operating as a purely academic project [LinkedIn] [Ramp Jobs].
Partially corroborated -- Core company identity is corroborated by Crunchbase and the company website, but several milestone details remain company-described or only partially corroborated in public records.
Under the Hood
MIXED
Coherence Neuro is trying to apply implantable neurotechnology to oncology, a narrower and more technically specific claim than the broader brain-computer interface label suggests. Public materials describe two linked systems: SOMA, the company’s therapeutic implant program, and CIPHER, the sensing and stimulation probe now associated with its early human work [Tech Funding News, November 2025] [coherenceneuro.com] [massdevice.com]. Tech Funding News described SOMA-1 as a system designed to listen to the body’s electrical cues as disease evolves and use stimulation in response, while the company website frames the broader approach as treating disease with implantable electronic devices [Tech Funding News, November 2025] [coherenceneuro.com].
The product detail that appears most consistently across public sources is the glioma and brain-tumor use case. The company’s product page says SOMA is intended for people with glioblastoma and is powered by an overnight charge that supports all-day battery life through a wearable magnetically attached charger [coherenceneuro.com/product]. A later trade publication described SOMA-1 as MRI-compatible and minimally invasive, intended to be implanted during existing neurosurgery to monitor and treat gliomas in real time [The World of Implantable Devices, January 2026]. Those are still investigational claims, not evidence of approval or clinical efficacy, but they do show a product concept that is more concrete than a research thesis alone [The World of Implantable Devices, January 2026] [coherenceneuro.com/product].
CIPHER appears to be the nearer-term technical wedge because it is the system tied to reported intraoperative use. Multiple sources describe it as a flexible, electrode-dense thin-film cortical probe for recording and stimulation, and public reporting says it was temporarily placed in three patients undergoing brain tumor removal surgery at Royal Melbourne Hospital [WIRED] [TMG Pulse] [BrainPatch® Blog]. Dr. Andrew Morokoff is identified in secondary coverage as leading the initiation of the first-in-human clinical trial there [TMG Pulse]. The company’s open roles also point to a hardware-heavy buildout across electrical engineering, automation, lab operations, surgical development, and clinical science, with some stack implications around test infrastructure and translational operations rather than software-first distribution (inferred from job postings) [Ramp Jobs].
Reasoned from indirect evidence -- Product architecture is partly corroborated by Tech Funding News, company pages, and secondary trade coverage, but several key technical and clinical details remain company-reported or supported by a single source.
Market Research
PUBLIC
The market matters now because Coherence Neuro sits at the intersection of two active healthcare spending priorities, brain tumor care and neurotechnology, but the public record is still too thin to size its exact addressable segment with confidence from named third-party market reports [WIRED] [Tech Funding News, November 2025].
Public evidence supports the clinical problem more clearly than the commercial market map. Coherence is developing implantable systems aimed at gliomas and glioblastoma, with a stated premise that continuous sensing and stimulation could add information between periodic scans and potentially alter disease progression workflows [The World of Implantable Devices] [ICI Innolabs, June 2026]. That matters because standard brain tumor management is episodic by design, centered on surgery, imaging, radiation, and drug therapy, while Coherence is positioning around real-time monitoring during and after neurosurgery rather than around a conventional pharmaceutical pathway [The World of Implantable Devices] [WIRED Middle East].
The most visible demand driver in the sources is not broad hospital procurement yet, but investigator interest in whether tumor-neural signaling can be measured in vivo. The reported first-in-human CIPHER work at Royal Melbourne Hospital, led by Dr. Andrew Morokoff, suggests early clinical curiosity around intraoperative neurophysiological monitoring in brain tumor surgery, which is a narrower and more realistic initial entry point than a fully commercial therapeutic platform [TMG Pulse] [WIRED]. Hiring also points in that direction: roles in clinical science, surgical development, test engineering, and vivarium operations fit a company preparing investigational studies and device iteration rather than near-term scaled sales deployment [Ramp Jobs].
The adjacent markets are easier to identify than the core market size. Coherence touches several established spending buckets: neuromodulation devices, brain-computer interfaces, intraoperative monitoring, and oncology devices, with substitution pressure from existing imaging-led surveillance and standard-of-care drug regimens if the company cannot show clinically useful signal quality or therapeutic effect [massdevice.com] [The World of Implantable Devices]. That mix can help if the company proves utility, because acquirers and strategic partners already exist across medtech and neurotech, but it also means evidence thresholds are likely to be set by both oncology outcomes and device safety expectations rather than by novelty alone [massdevice.com] [WIRED Middle East].
Regulation is the other gating variable. Every public source describes investigational or first-in-human activity, not an approved product, and the lead product is framed as MRI-compatible and intended for implantation during existing neurosurgery, which implies a development path shaped by device safety, surgical workflow integration, and human factors as much as by headline efficacy [The World of Implantable Devices, January 2026] [Tech Funding News, November 2025]. In practical terms, the market may be large in principle, but the near-term obtainable segment is likely limited to specialist neurosurgical centers willing to participate in early studies until there is clearer evidence on repeatability, benefit, and regulatory progress [TMG Pulse] [Ramp Jobs].
| Market lens | Public claim | Source |
|---|---|---|
| Core indication focus | Coherence's public-facing development focus includes gliomas and glioblastoma | [ICI Innolabs, June 2026]; [coherenceneuro.com/product] |
| Initial care setting | First reported human use is intraoperative testing during brain tumor removal surgery at Royal Melbourne Hospital | [WIRED]; [TMG Pulse] |
| Adjacent market 1 | Product concept overlaps neuromodulation through targeted stimulation | [Tech Funding News, November 2025]; [massdevice.com] |
| Adjacent market 2 | Product concept overlaps brain-computer interfaces through sensing and stimulation hardware | [The World of Implantable Devices, January 2026]; [TMG Pulse] |
| Near-term buyer universe | Early users appear more likely to be research hospitals and neurosurgical investigators than broad provider networks | [TMG Pulse]; [Ramp Jobs] |
The table shows why this is still a market formation story rather than a standard medtech rollout. The public evidence anchors the use case, care setting, and adjacent budgets, but it does not yet support a clean TAM or penetration model from named external market research.
Partially corroborated -- Market framing is grounded in named public product and clinical-use sources, but no independent third-party market sizing report was captured for this section.
Competition and Substitutes
MIXED
Coherence Neuro is not competing head-on with a single established product category so much as it is trying to assemble a new one at the intersection of neuromodulation, brain-computer interfaces, and oncology, which leaves its nearest alternatives split across adjacent segments rather than cleanly named peers in the source set [Tech Funding News, November 2025] [massdevice.com].
The competitive map, on the public record available here, breaks into three layers. The second is neuro-oncology monitoring and treatment workflows centered on imaging, surgery, and drug therapy, which are the practical substitute today because Coherence Neuro's stated value proposition is higher-frequency sensing and eventual responsive stimulation for glioma care rather than a replacement for existing standard-of-care treatment [The World of Implantable Devices] [WIRED Middle East]. The third is research-use cortical sensing tools used intraoperatively, where CIPHER appears to fit most naturally at present, since the first reported use is in brain-tumor surgery at Royal Melbourne Hospital and the initial trial is described as intraoperative neurophysiological monitoring rather than a commercial chronic implant deployment [TMG Pulse] [BrainPatch® Blog].
That positioning creates a real but narrow edge today. Publicly, the company can point to a coherent product ladder: CIPHER as an early cortical sensing and stimulation probe in surgery, and SOMA as the longer-term fully implantable therapeutic system intended for continuous monitoring and treatment [TMG Pulse] [Tech Funding News, November 2025]. If that sequencing holds, the advantage is not distribution yet, and not regulatory clearance yet, but data and workflow familiarity: intraoperative use could generate disease-specific signal insight that is more relevant to glioma than a general-purpose BCI dataset, and that in turn could inform a closed-loop implant thesis [The World of Implantable Devices] [ICI Innolabs, June 2026]. The durability of that edge is still unproven. It becomes stronger only if the company converts early human procedures into a proprietary signal library and repeatable clinical relationships. Otherwise, it remains perishable because better-capitalized neurotechnology groups could pursue the same clinical wedge once the signal hypothesis looks credible.
The exposure is clearer than the moat. Coherence Neuro has disclosed a $10 million seed round led by Topology Ventures, with participation from a broad investor syndicate, which is enough to fund early device and clinical work but modest relative to the capital usually required for implantable therapeutics, chronic follow-up, manufacturing, and regulatory progression in class-defining medtech categories [Tech Funding News, November 2025] [massdevice.com]. The company is also exposed to category substitution from existing neuro-oncology practice. MRI, surgery, pathology, and drug regimens already own physician attention and reimbursement pathways, while Coherence Neuro is still making the case that neural activity can serve as a useful real-time biomarker of tumor progression and response [The World of Implantable Devices] [coherenceneuro.com]. In practical terms, the nearest competitor over the next 18 months may be the current care pathway rather than another startup.
The most plausible near-term competitive scenario is a bifurcation between companies that can turn clinical novelty into repeatable evidence and those that cannot. Coherence Neuro is the likely winner if the Royal Melbourne work expands into a recognizable early clinical dataset and shows that intraoperative or temporary sensing yields information that imaging cadence misses, because that would give the company a disease-specific claim instead of a platform story [TMG Pulse] [WIRED Middle East]. The likely loser if that evidence does not appear is Coherence Neuro itself, not because the concept lacks interest, but because adjacent neuromodulation and BCI developers would still retain stronger infrastructure, while standard neuro-oncology workflows would continue to dominate care by default. On today's public evidence, the company is differentiated more by thesis and early clinical intent than by an already-defended market position.
Opportunity
Upside case
PUBLIC The prize here is unusually large if the company can turn an investigational brain interface into a repeatable clinical system, because the target is not a marginal workflow tool but a new treatment layer for glioma care that could sit inside existing neurosurgery and generate continuous disease-state data between scans [Tech Funding News, November 2025] [The World of Implantable Devices, 2026-01-17] [The World of Implantable Devices].
The clearest upside case is that Coherence Neuro becomes the first credible platform for closed-loop neuromodulation in neuro-oncology. Public evidence is still early, but it is directionally coherent: the company says it is building SOMA as a fully implantable therapeutic brain stimulation system, Tech Funding News described SOMA-1 as a system intended to listen to electrical cues as disease evolves and guide the body toward health, and secondary coverage has tied the early CIPHER study to a longer-term implant program rather than a one-off surgical instrument [coherenceneuro.com/product] [Tech Funding News, November 2025] [TMG Pulse] [BrainPatch® Blog]. That does not establish clinical efficacy, but it does make the opportunity reachable in a specific way. If CIPHER can map tumor-linked neural signatures during surgery and SOMA can later monitor and stimulate around those signatures in chronically implanted settings, Coherence would own both the sensing layer and the therapeutic loop in a category with few publicly visible peers focused on brain tumors [TMG Pulse] [ICI Innolabs, June 2026].
A second reason the upside is not purely aspirational is execution tempo. Multiple public sources report that Coherence temporarily tested or implanted its brain interface in three patients undergoing brain tumor surgery at Royal Melbourne Hospital, with Dr. Andrew Morokoff identified in one source as leading the first-in-human CIPHER study [WIRED] [Inshorts] [TMG Pulse]. The sourcing is mixed and still mostly secondary, but early human use, combined with seven open roles spanning electrical engineering, clinical science, test development, and surgical human factors, suggests a company staffing for device iteration and clinical expansion rather than basic concept work alone [Ramp Jobs].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Intraoperative wedge to chronic therapy | CIPHER becomes a recognized intraoperative mapping tool in brain-tumor surgery, then feeds directly into SOMA implantation and longitudinal monitoring | Additional first-in-human data and a clearer link between surgical recordings and post-op treatment decisions [TMG Pulse] [BrainPatch® Blog] | Public materials already describe CIPHER as the first reported clinical step and SOMA as the follow-on implant architecture [Tech Funding News, November 2025] [The World of Implantable Devices, 2026-01-17] |
| Closed-loop standard for glioma management | SOMA-1 is implanted during existing neurosurgery and becomes part of high-acuity glioma care at leading centers | Evidence that real-time sensing adds information between conventional imaging intervals and that stimulation can be delivered safely in an MRI-compatible format [The World of Implantable Devices, 2026-01-17] [The World of Implantable Devices] | The public clinical vision is specific: continuous monitoring of progression and response in a disease area where current workflows often rely on scans spaced months apart [The World of Implantable Devices] |
| Neuro-oncology data platform | The company builds a proprietary dataset linking cortical electrical activity, tumor evolution, and stimulation response, making it a partner of choice for hospitals and future therapeutics programs | More human cases across sites and a standardized pipeline for collecting and interpreting perioperative and longitudinal signals [WIRED] [TMG Pulse] [Ramp Jobs] | Coherence's product concept depends on sensing the tumor microenvironment and inferring how tumors interact with neural circuits over time, which naturally produces a differentiated data asset if the company scales case volume [coherenceneuro.com/product] [The World of Implantable Devices] |
The compounding mechanism, if it appears, is a clinical-data flywheel rather than a consumer network effect. Each additional surgical case can improve the mapping of tumor-associated electrical signatures, which can refine stimulation strategies, which can strengthen physician confidence and expand the set of hospitals willing to participate. Public sources already point to the first pieces of that loop: early procedures at Royal Melbourne Hospital, an explicit goal of measuring neural firing patterns as tumors interact with surrounding circuits, and hiring across clinical, hardware, and human-factors functions needed to operationalize that learning across programs [TMG Pulse] [The World of Implantable Devices] [Ramp Jobs].
That flywheel could deepen into distribution lock-in if Coherence succeeds in fitting implantation into existing neurosurgery rather than requiring an entirely new care pathway. The World of Implantable Devices described SOMA-1 as intended to be implanted during existing neurosurgery, and the company's own product page frames overnight charging and all-day battery life as part of a chronic-use design rather than a temporary monitor [The World of Implantable Devices, 2026-01-17] [coherenceneuro.com/product]. In medical devices, workflow fit matters as much as technical novelty. A system that enters through procedures surgeons already perform has a clearer route to adoption than one that demands net-new infrastructure.
The size of the win is best expressed as a platform outcome rather than a near-term revenue target. No public market-sizing source was provided in the research set, so the cleanest framing is conditional: if Coherence became the leading closed-loop implant company for glioma monitoring and intervention at major neurosurgical centers, the business could support a strategic or public-market valuation in the low-single-digit billions of dollars (scenario, not a forecast), based on the combination of implantable hardware, recurring clinical follow-up, and a proprietary longitudinal dataset. Public evidence today is too thin to benchmark that precisely, and no direct comparable was supplied in the source set, but the architecture described in public materials points to a company that is trying to own an entire treatment stack rather than sell a point device [Tech Funding News, November 2025] [massdevice.com] [coherenceneuro.com/product].
Reasoned from indirect evidence -- Core company, founder, funding, hiring, and product-direction claims are supported by Tech Funding News, company materials, Ramp Jobs, and secondary device coverage, but the upside case depends materially on early clinical signals that remain lightly corroborated and partly company-linked [Tech Funding News, November 2025] [Ramp Jobs] [TMG Pulse] [WIRED].
Sources
Open sources
[Tech Funding News, November 2025] Startup in spotlight: Coherence Neuro raises $10M to launch closed-loop neuro system for cancer treatment | https://techfundingnews.com/startup-in-spotlight-coherence-neuro-raises-10m-to-launch-closed-loop-neuro-dystem-for-cancer-treatment/
[massdevice.com] Coherence Neuro raises $10M seed round for BCI that aids in cancer treatment | https://www.massdevice.com/coherence-neuro-raises-10m-seed-round-for-bci-that-aids-in-cancer-treatment/
[Crunchbase] Coherence Neuro - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/opto-biosystems
[TMG Pulse] Coherence Neuro company profile and CIPHER trial coverage | https://tmgpulse.com/
[The World of Implantable Devices, January 2026] Coherence Neuro develops SOMA-1 for glioma monitoring and treatment | https://theworldofimplantabledevices.com/
[ICI Innolabs, June 2026] Coherence Neuro is testing a brain-computer interface for detecting and managing brain tumors | https://iciinnolabs.com/
[coherenceneuro.com] Coherence Neuro website | https://www.coherenceneuro.com
[Forbes] Elise Jenkins profile and background | https://www.forbes.com/
[Department of Engineering] Elise Jenkins Cambridge research profile | https://www.eng.cam.ac.uk/
[Ramp Jobs] Coherence Neuro jobs listings | https://jobs.ashbyhq.com/ramp
[coherenceneuro.com/product] Coherence Neuro product page | https://www.coherenceneuro.com/product
[WIRED] Coherence Neuro brain-tumor surgery testing coverage | https://www.wired.com/
[BrainPatch® Blog] CIPHER cortical probe and initial trial description | https://brainpatch.com/
[WIRED Middle East] Coherence Neuro brain-computer interface for tumor growth management | https://wired.me/
[Centre for Science and Policy] Elise Jenkins profile | https://www.csap.cam.ac.uk/
[LinkedIn] Coherence Neuro | https://www.linkedin.com/company/coherenceneuro
[Inshorts] Coherence Neuro temporary testing in three patients | https://inshorts.com/
Articles about Coherence Neuro
- Coherence Neuro's Implant Listened to Three Tumors in the Operating Room — The neurotech startup, backed by Topology Ventures and Founders Fund, is developing a device that senses and stimulates to manage brain tumors.